An Integrated Platform
With the Ncardia platform, we can assess the efficacy and safety of candidate compounds on human in vitro translational models. We can put our large-scale manufacturing capabilities to work to ensure reproducible high-throughput screenings of large libraries against the same batch of cells from beginning to end. And we can screen any modality – small molecule, RNA therapeutic, monoclonal antibody or gene therapy – using physiologically relevant human iPSC-based phenotypic assays.
Find out more